Lithium Orotate and memory and cognitive decline
What 4 graded rows on lithium orotate agree on for memory and cognitive decline, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Lithium Orotate page, reviewed Oct 13, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Lithium Orotate page, with its PubMed record.
Your question
Lithium Orotate and memory and cognitive decline
4 rows · 648 peopleSplit. 2 rows found an improvement, 1 found no difference and 1 had mixed results.
- CGrade C× 1
- DGrade D× 3
- Rows
- 4
- Trials
- 9
- People
- 648
- Pooled reviews may count some twice
Where they differ
From the rowsThe best-graded row, grade C, is a meta-analysis of 394 people (2026) and reported mixed results.
The row that found no difference is newer (2026) than the 2 rows that found an improvement (2013 to 2019).
1 row with mixed results is left out of this comparison.
The rows
2 improved · 1 no difference · 1 mixed- DGrade DCognitive scores (MMSE) in Alzheimer's disease · Improved
RCT · n 113 · 2013 · Adults with Alzheimer's disease at a geriatric clinic in São Paulo, Brazil (58 lithium, 55 placebo randomised)
300 µg (0.3 mg) lithium once daily · 15 months
MMSE scores did not fall in the lithium group, while the placebo group's scores declined, with significant differences from month 3 onward.
Row on the Lithium Orotate page · PubMed 22746245 (opens PubMed)
- DGrade DCognitive and functional decline in amnestic mild cognitive impairment · Improved
RCT · n 61 · 2019 · Community-dwelling, physically healthy older adults with amnestic mild cognitive impairment (Brazil)
Titrated to subtherapeutic blood lithium of 0.25–0.5 mEq/L · 2 years double-blind, then 2 years single-blind
The placebo group declined on cognitive and functional scores while the lithium group stayed stable over 2 years; lithium was linked to better memory and attention at 24 months and higher CSF amyloid-β42 at 36 months.
Row on the Lithium Orotate page · PubMed 30947755 (opens PubMed)
- DGrade DMemory, brain volume and BDNF in mild cognitive impairment · No difference
Pilot RCT · n 80 · 2026 · Adults aged 60+ with mild cognitive impairment (USA); about a quarter were amyloid-positive
Low dose titrated to tolerance; completers averaged 195 mg/day carbonate (about 37 mg lithium), mean blood level 0.17 mEq/L · 2 years
None of the 6 co-primary outcomes met the significance threshold. Verbal delayed recall fell 0.73 vs 1.42 points a year (difference 0.69, 95% CI 0.01–1.37, P = .05). Diarrhoea 29% vs 15%; serious adverse events 29% vs 23%, none judged definitely treatment-related.
Row on the Lithium Orotate page · PubMed 41770546 (opens PubMed)
- CGrade CCognition, function and behaviour in Alzheimer's dementia or amnestic MCI · Mixed
Meta-analysis, 6 studies · n 394 · 2026 · Randomised controlled trials of lithium versus placebo or standard care in Alzheimer's dementia or amnestic MCI
Varied by trial · Varied by trial
No significant MMSE benefit (MD −1.61, 95% CI −4.11 to 0.88); ADAS-Cog MD −1.82 (−3.05 to −0.60), both with high heterogeneity. No consistent benefit for memory, function, behavioural symptoms or CSF biomarkers. No rise in serious adverse events; drug-related adverse events were more frequent.
Row on the Lithium Orotate page · PubMed 41177743 (opens PubMed)